MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11751-11759

  Li, Zhipeng ^a   Li, Xu ^b   Yu, Chao ^a   Wang, Min ^b   Peng, Feng ^b   Xiao, Jie ^a   Tian, Rui ^b   Jiang, Jianxin ^a   Sun, Chengyi ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cisplatin; FGFR3; miR 100; Pancreatic cancer

Indexed keywords

3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; CISPLATIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; MICRORNA; MIRN100 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL; BINDING SITE; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING SITES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MICRORNAS; PANCREATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA INTERFERENCE; RNA, MESSENGER; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925284861     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2271-8     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: Cancer J Clin. 2010;60:277–300.
2. Chen W, Zheng R, Zhang S, Zhao P, Li G, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res = Chung-kuo yen cheng yen chiu. 2013;25:10–21.
3. Hirata K, Egawa S, Kimura Y, Nobuoka T, Oshima H, et al. Current status of surgery for pancreatic cancer. Dig Surg. 2007;24:137–47.
4. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
5. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005;11:1753–61.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.
7. Feng W, Feng Y. MicroRNAs in neural cell development and brain diseases. Sci Chin Life Sci. 2011;54:1103–12.
8. Bian S, Sun T. Functions of noncoding RNAs in neural development and neurological diseases. Mol Neurobiol. 2011;44:359–73.
9. Papagiannakopoulos T, Kosik KS. MicroRNAs: regulators of oncogenesis and stemness. BMC Med. 2008;6:15.
10. Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, et al. Tumor suppressor microRNAs: a novel non-coding alliance against cancer. FEBS Lett. 2014;32:74–81.
11. Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Gen. 2014;5:54.
12. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol. 2011;29:265–9.
13. Reis ST, Timoszczuk LS, Pontes-Junior J, Viana N, Silva IA, et al. The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer. Clinics. 2013;68:652–7.
14. Gebeshuber CA, Martinez J. miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene. 2013;32:3306–10.
15. Chen D, Sun Y, Yuan Y, Han Z, Zhang P, Chen D, et al. PLoS Genet. 2014;10:e1004177.
16. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010;24:447–63.
17. Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27:1238–44.
18. Radulovich N, Qian JY, Tsao MS. Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol. 2008;439:1–13.
19. Zhang L, Mizumoto K, Sato N, Ogawa T, Kusumoto M, et al. Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin. Cancer Lett. 1999;142:129–37.
20. Jung DE, Wen J, Oh T, Song SY. Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas. 2011;40:1180–7.
21. LaConti JJ, Shivapurkar N, Preet A, Deslattes Mays A, Peran I, et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One. 2011;6:e20687.
22. Panarelli NC, Chen YT, Zhou XK, Kitabayashi N, Yantiss RK. MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas. 2012;41:685–90.
23. Giroux V, Dagorn JC, Iovanna JL. A review of kinases implicated in pancreatic cancer. Pancreatol: Off J Int Assoc Pancreatol. 2009;9:738–54.
24. Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993;53:5289–96.
25. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S, et al. Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas. 2003;26:344–9.
26. Hammel P, Mornex F, Deplanque G, Mitry E, Levy P, et al. Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: a multicenter phase II study. J Clin Oncol. 2009;27:4617.